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ABSTRACT
Objectives: Various physiological and pathological conditions can induce significant variations in plasma concentrations 
of tumor markers, such as CA 19-9, which is present in the serum and amniotic fluid of pregnant women. Herein, we aimed 
to determine the clinical importance of maternal serum CA 19-9 levels in the diagnosis of neural tube defects (NTDs).
Material and methods: A total of 100 women were included in this controlled cross-sectional study. Thirty-three patients 
whose pregnancies were complicated by isolated meningocele or meningomyelocele constituted the study group, whereas 
33 normal, healthy pregnant women constituted the control group, and 34 age- and body mass index (BMI)-matched 
non-pregnant women were chosen for the validation group. 
Results: The mean maternal serum CA 19-9 levels were 17.2 ± 17.0 IU/mL, 7.1 ± 5.9 IU/mL, and 4.7 ± 3.6 IU/mL in the study, 
control, and validation groups, respectively (p < 0.001). ROC analyses showed that elevated CA 19-9 values may predict 
NTDs (p < 0.001). The cut-off value for CA 19-9 was found to be 9.6 IU/mL at 70% (51%–84%, 95% CI) sensitivity and 84% 
(74%–92%, 95% CI) specificity.
Conclusions: CA 19-9 may be a promising noninvasive marker for NTDs. Further studies are needed to reveal the clinical 
applicability and diagnostic potential of maternal serum CA 19-9 levels in the identification of NTDs.
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INTRODUCTION
Neural tube defect (NTD) is the second most common 
cause of congenital anomalies, after congenital heart dis-
ease. The etiology of NTDs has been extensively studied 
and it is believed that they are multifactorial complex disor-
ders. Genetic predisposition, socioeconomic status, diabe-
tes mellitus, and environmental causes, such as nutritional 
deficiency, anticonvulsant agents, and hyperthermia, may 
affect the risk for NTDs [1, 2]. The reported incidence of 
NTDs (of which myelomeningocele is the most common) 
varies between different geographic regions; the rate has 
been reported to be as low as 1 per 1,000 live births in 
European countries, and as high as 15 per 1,000 live births 
in some Asian countries, such as India [3]. NTDs originate 
from the failure of the neurulation process during embryonic 
development, 3–4 weeks after conception [4]. These defects 
are divided into two types: cranial and spinal. Encephalocele, 
anencephaly, and iniencephaly are lethal cranial defects, 
while meningocele and meningomyelocele are open spinal 
NTDs, and spina bifida occulta is a closed spinal NTD [5]. 
The exact cause of NTDs is not known, but a diet poor in 
folic acid increases the risk; folic acid supplementation is 
known to decrease the rate of NTDs by 27–40% [6]. NTDs 
are generally diagnosed via imaging methods, and these 
pregnancies are often terminated. 
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Carbohydrate antigen 19-9 (CA 19-9), also called sia-
lylated Lewis antigen, is synthesized by normal human pan-
creatic and biliary ductal cells and by gastric, colon, endome-
trial, and salivary excretory epithelial tissues [7, 8]. CA 19-9 is 
commonly used as a tumor marker for certain epithelial-type 
gastrointestinal cancers, particularly pancreatic. However, 
elevated serum levels of CA 19-9 can be detected in several 
benign pancreatic, hepatic, and biliary conditions, such as 
acute and chronic pancreatitis, cholelithiasis, cholecystitis, 
achalasia, acute hepatitis, and hepatic cirrhosis, and in be-
nign lung diseases, such as bronchiolitis, emphysema, and 
bronchiectasia [9, 10]. Systemic diseases, such as diabetes 
mellitus, rheumatic disorders, and autoimmune disorders, 
may also increase CA 19-9 serum levels. In addition, it is used 
as a follow-up marker for chronic organ-specific inflamma-
tory conditions, such as prostatitis [11].
The idea of prenatal screening for serious birth defects 
began in the 1970s with the discovery of high maternal 
serum levels of alpha-fetoprotein (AFP) in pregnancies com-
plicated by open NTDs. It was hypothesized that AFP, one 
of several oncofetal proteins synthesized in large amounts 
by the fetal liver, leaks into the amniotic fluid from the open 
side of the central nervous system, and leads to high ma-
ternal serum AFP levels. Similarly, the oncofetal antigen CA 
19-9 may diffuse to the maternal circulation through the 
amniotic fluid in open NTDs. Previous experimental stud-
ies in animals showed that exposure of the spinal cord to 
amniotic fluid contributes to local tissue inflammation and 
associated neurological sequelae [12, 13]. Neuronal inflam-
mation can also lead to elevated serum CA 19-9 levels [14]. 
Neutrophil and lymphocyte cells play an important 
role in inflammatory conditions, and their numbers and 
structures may change in case of inflammation. The neu-
trophil-to-lymphocyte ratio (NLR) is a simple biomarker 
for inflammation; in a recent study, NLR was introduced as 
a marker in various diagnostic and prognostic gynecological 
procedures [15]. NLR has been also studied in some acute 
and chronic inflammatory diseases of the central nervous 
system. It was suggested as a potential biomarker in the 
differential diagnosis of acute meningitis [16], and as a pre-
dictor of disease activity and severity in multiple sclerosis 
[17]. In the present study, we aimed to investigate serum CA 
19-9 levels in pregnancies with spinal NTDs.
MATERIAL AND METHODS
This prospective, cross-sectional case-control study 
was conducted at the Zekai Tahir Burak Women’s Health 
Education and Research Hospital, Ankara, a referral tertiary 
hospital located in the central region of Turkey, with approxi-
mately 20,000 deliveries per year. A total of 100 pregnant 
and non-pregnant women were recruited from high-risk 
pregnancy, antenatal, and family planning clinics between 
January 2015 and August 2015, after the study received ap-
proval from the hospital’s ethics committee. Informed con-
sent was obtained from each participant. All of the patients 
were in the second trimester of pregnancy (18–22 weeks), and 
each underwent a detailed prenatal ultrasound screening 
with a Voluson 730 Expert ultrasound machine (GE Medical 
systems, Kretztechnik GmbH & OHG, Zipf, Austria) equipped 
with a 3.5–5-MHz curvilinear transabdominal transducer. 
Ultrasonographic examinations were performed by 
a high-risk-pregnancy specialist in the antenatal polyclinic. 
Thirty-three patients whose pregnancies were complicated 
by isolated meningocele or meningomyelocele constituted 
the study group (group I), whereas 33 normal, healthy preg-
nant women constituted the control group (group II) and 
34 age- and body mass index (BMI)-matched non-pregnant 
women, who had given birth at least 6 weeks earlier and 
had applied for birth control methods, were chosen for 
the validation group (group III). None of the patients in the 
validation group had not been used a birth control method 
yet. Most of the patients with NTDs were referred by other 
hospitals in the region. The exclusion criteria were a known 
history or evidence of acute infection; chronic inflamma-
tory disease; respiratory, rheumatologic, or immunologic 
disease; pancreatic, hepatic, or biliary tract disease; gesta-
tional diabetes; hypertensive disorders; a previous history 
of ovarian cysts; or any malignancy. It was confirmed that 
postpartum or postabortion examination of the fetuses 
showed no additional anomalies in the study group. Pa-
tients with a suspected diagnosis of NTD in the detailed 
ultrasound scan were excluded from the study. All patients 
were also evaluated during the ultrasound examination for 
the presence of any adnexal masses, and no such masses or 
cysts were observed. 
The data obtained from the patients were age, BMI, 
gestational age at blood draw in the pregnant patients, 
obstetrical history (gravidity, parity, and number of live 
children and abortions), and smoking status. Blood samples 
were taken from pregnant women at the time of applying 
for ultrasound examination whereas they were collected 
from non-pregnant women during the early follicular phase 
(day 2–4). The patients’ height and weight were measured 
with a professional calibrated device. BMI was calculated 
based on the following formula: weight (kg)/height (m2). 
Gestational weeks were calculated according to last men-
strual period, or with ultrasound during the first trimester 
in patients who did not know their last menstrual period.
Following at least 8 hours of fasting, approximately 5 cc 
of blood was drawn from the antecubital vein and poured 
into gel tubes and hematologic sample tubes containing an-
ticoagulant. The blood samples were centrifuged at 4100 × g 
for 10 minutes. The sera were then separated, and were 
studied immediately. Serum CA 19-9 levels were measured 
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with an Analytics E170 (Elecsys module) immunoassay ana-
lyzer (Roche Diagnostics GmbH, Mannheim, Germany) using 
the electrochemiluminescence immunoassay method. He-
matologic parameters were investigated using the Coulter 
LH–780 hematology blood analyzer (Beckman Coulter Inc., 
Brea, CA, USA). NLR was defined as absolute neutrophil 
count divided by absolute lymphocyte count. All blood 
samples were analyzed in the biochemistry laboratory of 
our hospital. 
Statistical analysis
Statistical Package for the Social Sciences version 
17.0 (SPSS Inc., Chicago, IL, USA) was used for statistical 
analysis. Descriptive statistics were used to demonstrate the 
mean ± standard deviation and the median (range) for con-
stant variables, whereas nominal variables were expressed 
as case numbers and percentages. For the analysis of the 
data, normality in the repeated measures was tested with 
the Kolmogorov-Smirnov or Shapiro-Wilk tests. One-way 
ANOVA was performed for data that demonstrated a nor-
mal distribution, and the Mann-Whitney U test and the 
Kruskal-Wallis test were used for data that did not demon-
strate a normal distribution. Homogeneity of the variances 
was evaluated with Levene’s test. Tukey’s honest significant 
difference (HSD) post-hoc test was used when the homo-
geneity requirement was met, and the Games Howell test 
was used otherwise. Nominal variables were analyzed with 
a chi-square test. In order to generate a cut-off value for CA 
19-9, a receiver operating characteristic (ROC) curve analysis 
was used. To determine the cut-off values corresponding to 
the CA 19-9, the Youden index (sensitivity + specificity − 1) 
was used, and the highest Youden index value was con-
sidered the cut-off. Pearson’s correlation analysis was used 
to determine the relationship between CA 19-9 and NLR. 
Statistical significance was accepted as p < 0.05.
RESULTS
A total of 100 women were included in this study. 
Thirty-three pregnant women whose pregnancies were 
complicated by spinal NTDs were classified as group I, 
33 healthy pregnant women without fetal malforma-
tions were classified as group II, and group III consisted 
of 34 healthy non-pregnant women. Of the 33 patients in 
group I, 10 had meningocele and 23 had meningomyelocele. 
Table 1 compares the demographic characteristics of the 
groups. All three groups were similar in terms of age and 
BMI. Median parity and the number of live children were 
significantly higher in the validation group compared with 
the other two groups (p < 0.05). The rate of current smok-
ers was also higher in this group, but the difference was 
statistically insignificant. There was no statistically significant 
difference between the pregnant groups regarding fetal 
gender and gestational age at blood draw (19.9 ± 2.2 weeks 
vs. 20.1 ± 1.5 weeks, respectively; p = 0.163). 
Twenty-four (72.3%) patients in group I chose to termi-
nate their pregnancies, and uncomplicated medical abor-
Table 1. Comparison of demographics and CA19.9 levels of the groups
Group I 
(n: 33)
Group II 
(n: 33)
Group III 
(n: 34) p
p
I–II I–III II–III
Age (years) 27.2 ± 6.1 26.4 ± 4.8 25.9 ± 5.1 0.583 0.811 0.557 0.911
BMI [kg/m2] 27.1 ± 4.8 26.9 ± 3.6 24.8 ± 5.8 0.080 0.969 0.100 0.163
Gravida 2 (1–6) 2 (1–4) 2 (0–4) 0.313 0.935 0.184 0.205
Parity 1 (0–2) 1 (0–2) 2 (0–4) 0.005 0.634 0.003 0.016
Live children 0 (0–2) 1 (0–3) 2 (0–4) 0.004 0.410 0.002 0.010
Abortion 0 (0–4) 0 (0–2) 0 (0–2) 0.246 0.099 0.635 0.205
Smoker n (%) 3 (9.1) 3 (9.1) 8 (23.5) 0.146 1.000 0.113 0.113
Fetal gender n (%)
Male 
Female 
 
14 (42.4)
19 (57.6)
 
17 (51.5)
16 (48.5)
0.450
GW (weeks) 19.9 ± 2.2 20.5 ± 1.5 0.163
CA19.9 [U/mL] 17.2 ± 17.0 7.1 ± 5.9 4.7 ± 3.6 < 0.001 0.008 0.001 0.109
WBC count 9.9 ± 2.3 9.7 ± 2.0 7.5 ± 1.6 < 0.001 0.901 < 0.001 < 0.001
Neutrophile 7.3 ± 1.8 7.2 ± 1.8 4.6 ± 1.3 < 0.001 0.959 < 0.001 < 0.001
Lymphocyte 1.8 ± 0.5 1.9 ± 0.4 2.0 ± 0.5 0.135 0.536 0.112 0.612
NLR 4.3 ± 1.2 4.0 ± 1.5 2.4 ± 0.7 < 0.001 0.691 < 0.001 < 0.001
BMI — body mass index; AFP — alpha-feto protein; MoM — multiple of the median; WBC — white blood cell; NLR — neutrophile-to-lymphocyte ratio;  
GW — gestational week. Values are given as mean ± standard deviation and median (range). A p value < 0.05 is considered as statistically significant
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tions using misoprostol were performed on all of them. Two 
of the remaining nine (27.3%) patients delivered vaginally, 
while seven patients gave birth via cesarean section. Birth 
weights and 5-minute Apgar scores in group I ranged from 
2590–3890 g and 7–10 points, respectively. In group II, 
there were more vaginal deliveries than cesarean births 
(24 vs. 9). Birth weights and 5-minute Apgar scores ranged 
from 1650–3980 g and 0–10, respectively, in this group. 
There were also three patients with fetal growth restriction, 
one patient with stillbirth, and one patient with a preterm 
birth in group II. A history of previous cesarean section 
and fetal distress were the most common indications for 
cesarean section in both groups.
The mean maternal serum CA 19-9 levels were 17.2 ± 17.0, 
7.1 ± 5.9, and 4.7 ± 3.6 in groups I, II, and III, respectively 
(p < 0.001) (Fig. 1). When a subgroup analysis was performed, 
a weak but significant difference was observed between 
the meningocele and myelomeningocele cases in terms of 
mean CA 19-9 levels (10.2 ± 11.9 vs. 20.2 ± 18.3, respectively; 
p = 0.046). ROC curve analyses demonstrated that the AUC 
indicative of the CA 19-9 value for discriminating NTDs in 
pregnant patients was 0.762, with a confidence interval 
(CI) of 0.650–0.874 (Fig. 2). This difference was statistically 
significant (p < 0.001). According to the highest Youden 
index, the cut-off values for CA 19-9 were 9.6 IU/mL at 70% 
(51–84%, 95% CI) sensitivity and 84% (74–92%, 95% CI) 
specificity (Tab. 2). There were no correlations between CA 
19-9 and other numerical variables, except for a significant 
correlation between CA 19-9 and NLR in group I (correlation 
coefficient: 0.335, p = 0.001). No significant correlation was 
observed between CA 19-9 and NLR in the other groups. 
DISCUSSION
The present study aimed to evaluate the diagnostic 
value of maternal serum CA 19-9 levels in pregnancies 
complicated by spinal NTDs. We found that CA 19-9 was 
significantly increased in pregnancies with NTDs. Accord-
ing to this study, the CA 19-9 may be used as a diagnostic 
marker in these pregnancies.
Various physiological and pathological conditions, such 
as renal failure, pancreatic and hepatobiliary disease, lung 
disease, systemic disease, inflammation, menstruation, and 
pregnancy, can induce significant variations in plasma con-
centrations of tumor markers [9, 10, 18]. These markers have 
previously been investigated in the biologic fluids of healthy 
pregnant and non-pregnant women. The presence of con-
siderable concentrations of tumor markers during preg-
nancy may be attributed to their involvement in biological 
functions associated with fetal development, differentiation, 
and maturation [19]. One of these tumor markers, CA 19-9, 
is mostly used as a serum marker for malignancies, but it is 
also present in the serum and amniotic fluid of pregnant 
women [20]. In a prospective longitudinal study, serum 
concentrations of CA 125, CA 15-3, CA 19-9, and CEA were 
followed in healthy pregnant women throughout preg-
nancy [21]. No significant difference was observed in serum 
maternal serum CA 19-9 levels between the first and second 
trimesters; however, third trimester CA 19-9 levels showed 
Table 2. Sensitivity and specificity of CA19.9 for discriminating meningomyelocele 
AUC (95% CI) Cut-off value Sensitivity (95% CI) Specificity (95% CI) p
Ca19.9 0.762 (0.650–0.874) 9.6 70 (51–84) 84 (74–92) < 0.001
AUC — area under the curve; CI — confidence interval. A p value < 0.05 is considered as statistically significant
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Figure 1. Distribution of CA19.9 values between the groups
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Figure 2. ROC curve analysis of CA 19-9 for the diagnosis of spinal NTDs
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a significant increment compared to the first trimester. On 
the other hand, Thouitou et al. [18] reported no significant 
elevations in serum CA 19-9 values throughout pregnancy.
Tayyar and Tutus [22] reported that maternal serum 
and amniotic fluid CA 19-9 levels were elevated in primi-
gravidas and in pregnant women with female fetuses. In 
that study, genetic amniocentesis was performed during 
weeks 16–20 of the pregnancy. Similarly, we carried out the 
present study at around 20 weeks of pregnancy. There were 
no significant differences between the pregnant groups in 
terms of maternal age and fetal gender. Multiparity, which 
may affect serum levels of CA 19-9, was significantly higher 
in the validation cohort. However, the pregnant groups were 
similar regarding the median parity in our study. 
It has been shown that trophoblast cells express CA 
19-9, and amnion cells produce and secrete it into the am-
niotic cavity throughout gestation [23, 24]. There have been 
several reports that CA 19-9 might be used as a diagnostic 
marker in some pathological pregnancies. Amhad et al. [25] 
found that low AFP and increased CA 19-9 can be used as 
tumor markers in the diagnosis of molar pregnancies in con-
junction with clinical and sonographic findings and serum 
levels of human chorionic gonadotropin. It has also been 
suggested as a diagnostic marker for Down syndrome. How-
ever, there are conflicting reports on the use of CA 19-9 as 
a potential screening marker for the prenatal diagnosis of 
Down syndrome [26, 27]. To the best of our knowledge, the 
present study on the relationship between CA 19-9 and 
NTDs is the first such report in the literature. A previous 
study showed that exposure of the spinal cord to amniotic 
fluid leads to inflammation and tissue injury, although these 
histological findings are greater in the presence of meco-
nium [28]. In this context, we propose that the exposure of 
spinal cord defects to the amniotic fluid may initiate local 
inflammation, resulting in an elevated CA 19-9 level. Inflam-
matory cell infiltration was shown in one of the patients 
who accepted a histopathological examination in our study 
(Fig. 3). Similar to the AFP mechanism, the oncofetal antigen 
CA 19-9 may also diffuse to the maternal circulation through 
the amniotic fluid from open NTDs.
This was a preliminary study evaluating the diagnos-
tic value of CA 19-9 in pregnancies complicated by spi-
nal NTDs. The present study demonstrated that NLR had 
a significant positive correlation with maternal serum CA 
19-9 levels, which suggests an inflammatory process in the 
pathophysiology of the disease. The main limitation of this 
study was the small number of patients included. We also did 
not know the baseline CA 19-9 levels of the patients. How-
ever, we think that the addition of a validation group, which 
consisted of non-pregnant women, reduced this require-
ment. Additionally, ultrasonography is already a validated 
diagnostic tool for prenatal diagnosis of NTDs, and AFP is 
a known diagnostic serum marker. However, it is sometimes 
difficult to diagnose these types of anomalies, especially 
for inexperienced obstetricians, on fetal neurosonography. 
AFP values are sometimes found to be normal in small and 
closed defects or elevated in some other fetal anomalies.
We think that CA 19-9 may be a promising noninvasive 
marker for NTDs. It is a simple and easily applicable marker 
that can be used in combination with other biochemical 
markers, such as AFP, to improve the diagnostic accuracy of 
prenatal screening tests for this type of congenital anomaly. 
This insight can lead to further studies and further hypoth-
eses to test the diagnostic potential of CA 19-9 in NTDs. 
CONCLUSIONS
To conclude, the basic screening for fetuses with NTDs is 
ultrasound with a high detection rate. Biochemical markers 
may only serve as supplementary factors in the diagnosis, 
especially in the era of high resolution ultrasound machines 
and fetal magnetic resonance imaging.
Acknowledgement
We thank all the women who agreed to participate in this 
study.
Conflict of interest
The authors declare no conflict of interest.
REFERENCES
1. Detrait ER, George TM, Etchevers HC, [et al.]. Human neural tube defects: 
developmental biology, epidemiology, and genetics. Neurotoxicol 
Teratol. 2005, 27, 515–524.
2. Kandasamy V, Subramanian M, Rajilarajendran H, [et al.]. A Study on 
The Incidence of Neural Tube Defects in A Tertiary Care Hospital Over 
A Period of Five Years. J Clin Diagn Res. 2015, 9, QC01–QC04.
3. Hans JTD, Martin L, Akira H. Clinical Neuroembryology: Development 
and Developmental Disorders of the Human Central Nervous System. 
Springer, Heidelberg 2014.
4. Kaufman BA. Neural tube defects. Pediatr Clin North Am. 2004, 51, 
389–419.
5. Jorge AL. Neural Tube Defects. World Scientific Publishing Co Pvt. Ltd., 
Singapore 2011.
6. Center for Disease Control (CDC). Spina Bifida and Anencephaly Before 
and After Folic Acid Mandate United States, 1995–1996 and 1999–2000. 
Mortal Morb Wkly Rep. 2004, 53, 362–365.
7. Uygur-Bayramicli O, Dabak R, Orbay E, [et al.]. Type 2 diabetes mellitus 
and CA 19-9 levels. World J Gastroenterol. 2007, 13, 5357–5359.
8. Szekanecz E, Sándor Z, Antal-Szalmás P, [et al.]. Increased production of 
the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in 
Figure 3. Submeningeal hemorrhage and inflammatory cell 
infiltration are shown (H.E. 10x–40x)
813
Hakan Timur et al., CA 19-9 levels in spinal NTDs
www. journals.viamedica.pl/ginekologia_polska
rheumatoid arthritis: potential adhesion molecules in synovial inflam-
mation? Ann N Y Acad Sci. 2007, 1108, 359–371.
9. Park KH, Kim JS, Lee JH, [et al.]. Significances of serum level and immu-
nohistochemical stain of CA19-9 in simple hepatic cysts and intrahepatic 
biliary cystic neoplasms. Korean J Gastroenterol. 2006, 47, 52–58.
10. Vandemergel X, Vandergheynst F, Decaux G. Very high elevation of 
CA19-9 level in a patient with steatosis. Acta Gastroenterol Belg. 2005, 
68, 380–381.
11. Montalto M, Santoro L, Vastola M, [et al.]. Normalisation of high CA 19-9 
values in autoimmune hepatitis after steroidal treatment. Int J Immuno-
pathol Pharmacol. 2005, 18, 603–607.
12. Heffez DS, Aryanpur J, Rotellini NA, [et al.]. Intrauterine repair of 
experimental surgically created dysraphism. Neurosurgery. 1993, 32, 
1005–1010.
13. Heffez DS, Aryanpur J, Hutchins GM, [et al.]. The paralysis associated 
with myelomeningocele: clinical and experimental data implicating 
a preventable spinal cord injury. Neurosurgery. 1990, 26, 987–992.
14. Koide R, Taniguchi M, Ueki Y, [et al.]. A case of lumbar intradural and 
epidural abscesses presenting with elevated serum carcinoembryonic 
antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). No To Shinkei. 
2003, 55, 443–447.
15. Tokmak A, Yildirim G, Öztaş E, [et al.]. Use of Neutrophil-to-Lymphocyte 
Ratio Combined With CA–125 to Distinguish Endometriomas From Other 
Benign Ovarian Cysts. Reprod Sci. 2016, 23, 795–802.
16. Demirci S, Demirci S, Kutluhan S, [et al.]. The clinical significance of 
the neutrophil-to-lymphocyte ratio in multiple sclerosis. Int J Neurosci. 
2016, 126, 700–706.
17. Mentis AF, Kyprianou MA, Xirogianni A, [et al.]. Neutrophil-to-lymphocyte 
ratio in the differential diagnosis of acute bacterial meningitis. Eur J Clin 
Microbiol Infect Dis. 2016, 35, 397–403.
18. Touitou Y, Darbois Y, Bogdan A, [et al.]. Tumour marker antigens during 
menses and pregnancy. Br J Cancer. 1989, 60, 419–420.
19. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological 
fluids associated with pregnancy. Crit Rev Clin Lab Sci. 2007, 44, 151–178. 
20. Noci I, Borri P, Biagiotti R, [et al.]. Amniotic fluid levels of CA 19.9 and CA 15.3 in 
normal and Down’s syndrome pregnancies. J Perinat Med. 1995, 23, 237–241.
21. Ercan Ş, Kaymaz Ö, Yücel N, [et al.]. Serum concentrations of CA 125, CA 
15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study. Arch 
Gynecol Obstet. 2012, 285, 579–584.
22. Tayyar M, Tutus A. The effect of maternal age, parity, and fetal sex on the 
amniotic fluid and maternal serum levels of CA 125, CA 19.9, CA 15.3, 
and CEA. Int J Fertil Womens Med. 1999, 44, 256–259.
23. Bojić-Trbojević Z, Krivokuća MJ, Vrzić-Petronijević S, [et al.]. Expression 
of tumor associated antigens CA 15-3 and CA 19-9 in trophoblast of 
the normal human placenta. Eur J Gynaecol Oncol. 2012, 33, 281–284.
24. Kobayashi F, Sagawa N, Nanbu Y, [et al.]. Immunohistochemical localiza-
tion and tissue levels of tumor-associated glycoproteins CA 125 and 
CA 19-9 in the deciduas and fetal membranes at various gestational 
ages. Am J Obstet Gynecol. 1989, 160, 1232–1238.
25. Ahmad AE, Dehaghani AS, Shaker M, [et al.]. Clinical value of tumor markers 
in gestational trophoblastic diseases. J Reprod Med. 2008, 53, 930–934.
26. Koster MPH. Innovations in Down syndrome screening (thesis). 2010. 
Available from: http://igitur–archive.library.uu.nl/dissertatio ns/2010–
0903–200208/koster.pdf. 
27. Akinlade F, Cowans NJ, Kisanga MC, [et al.]. Maternal serum CA 19-9 
and CA 15-3 levels in pregnancies affected by trisomy 21. Prenat Diagn. 
2012, 32, 644–648.
28. Correia-Pinto J, Reis JL, Hutchins GM, [et al.]. In utero meconium exposure 
increases spinal cord necrosis in a rat model of myelomeningocele. 
J Pediatr Surg. 2002, 37, 488–492.
